Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabiralizumab +/- Nivolumab in Advanced Malignancies
NCT03158272Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2017
- Primary completion
- Oct 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabiralizumab in solid tumor (advanced stage) and multiple myeloma (MM) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events (AEs), Number of Participants With Serious Adverse Events (SAEs) and 4 more. Started May 2017; status: completed.
02
Drugs
cabiralizumab
03
Conditions
solid tumor (advanced stage)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03158272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158272.